Sentinel Node Biopsy Alone Versus Sentinel Node Biopsy Plus Axillary Dissection in cT2 cN0/1 Breast Cancer After Neoadjuvant Chemotherapy: 15-Year Results of a Prospective Interventional Study
- 18 November 2025
- journal article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (3) , 2255-2266
Abstract
Recent guidelines recommend sentinel lymph node biopsy (SNB) of cN1 breast cancer when the axilla is clinically clear after neoadjuvant chemotherapy (NAC).Keywords
Funding Information
- Ministero della Salute (“5 per 1000” funds for healthcare research)
This publication has 37 references indexed in Scilit:
- Selective Elimination of Breast Surgery for Invasive Breast CancerJAMA Oncology, 2025
- Safety of Targeted Axillary Dissection After Neoadjuvant Therapy in Patients With Node-Positive Breast CancerJAMA Surgery, 2023
- Nodal Recurrence in Patients With Node-Positive Breast Cancer Treated With Sentinel Node Biopsy Alone After Neoadjuvant Chemotherapy—A Rare EventJAMA Oncology, 2021
- Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant ChemotherapyJAMA Surgery, 2018
- Targeted axillary dissection after neoadjuvant therapy in breast cancerBritish Journal of Surgery, 2018
- Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary SurgeryJAMA Surgery, 2017
- Selective Surgical Localization of Axillary Lymph Nodes Containing Metastases in Patients With Breast CancerJAMA Surgery, 2015
- Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast CancerJAMA, 2013
- Adjusted Kaplan–Meier estimator and log‐rank test with inverse probability of treatment weighting for survival dataStatistics in Medicine, 2005
- Flexible regression models with cubic splinesStatistics in Medicine, 1989